Certain A Shares of Nanjing Vazyme Biotech Co., Ltd. are subject to a Lock-Up Agreement Ending on 15-NOV-2023.
November 14, 2023
Share
Certain A Shares of Nanjing Vazyme Biotech Co., Ltd. are subject to a Lock-Up Agreement Ending on 15-NOV-2023. These A Shares will be under lockup for 736 days starting from 9-NOV-2021 to 15-NOV-2023.
Details:
The Company?s actual controllers Cao Lin and Duan Ying, persons acting in concert Xu Xiaoyu, Zhang Lijun, Tang Bo, and Cao Shengbiao, and shareholders Nanjing Vazyme Investment Management Co., Ltd., Nanjing Boyingwei Investment Partnership Enterprise (Limited Partnership), and Nanjing Weizan Investment Partnership Enterprise (Limited Partnership) committed not to transfer or entrust to a third party the Company?s shares they hold directly or indirectly before the issuance, or allow the company to repurchase those shares within 36 months from the listing date. If within 6 months after the listing, the closing price of the shares is lower than the issuance price for 20 consecutive trading days or if the trading price is lower than the issuance price 6 months after listing, the lock-up period will be automatically extended for another 6 months. While holding office, Cao Lin, Xu Xiaoyu, Zhang Lijun, and Tang Bo committed to transfer not more than 25% of shares held each year.
The Company?s directors and senior management Hu Xiao Mei, Chen Miao, Bi Wenxin, Huang Jin, Company?s supervisors Zhang Guoyang, Huang Juan, and Feng Su, core technical employee Nie Junwei, and the other shareholders committed not to transfer or entrust to a third party the Company?s shares they hold directly or indirectly before the issuance, or allow the company to repurchase those shares within 12 months from the listing date. If within 6 months after the listing, the closing price of the shares is lower than the issuance price for 20 consecutive trading days or if the trading price is lower than the issuance price 6 months after listing, the lock-up period will be automatically extended for another 6 months. While holding office, Zhang Guoyang, Huang Juan, Feng Su, and Nie Junwei committed to transfer not more than 25% of shares held each year.
Nanjing Vazyme Biotech Co Ltd is China-based company principally engaged in biopharmaceuticals. The Company's main business is the technology research and development and product development of functional proteins such as enzymes, antigens, antibodies, and polymer organic materials. The Company's products include polymerase chain reaction (PCR), reverse transcription, gene sequencing series and other biological reagent products, quantum dot immunofluorescence reagents, latex enhanced immune turbidity reagents and colloidal gold immunochromatography reagents and other point-of-care testing (POCT) Diagnostic reagents and instruments.
NANJING VAZYME BIOTECH CO.,LTD 
